caa a22 4500 388110988 CHVBK 20180307125353.0 cr unu---uuuuu 161130e199912 xx s 000 0 eng 10.1017/S0924270800035857 doi S0924270800035857 pii (NATIONALLICENCE)cambridge-10.1017/S0924270800035857 Management of psychiatric adverse events with immunotherapy with interferon-alfa [Elektronische Daten] Immunotherapy with interferon-alfa has become standard therapy in selected patients with viral hepatitis and chronic myelogenous leukemia. In addition, it is used in a variety of other diseases, both as standard therapy and in clinical trials. Its use is expected to expand in the following decade. Interferon can cause (severe) neuropsychiatric side effects. These side effects are discussed. Adequate management of these side effects is important, as is close collaboration between the oncologist and the psychiatrist. The cornerstone of management is patient education: this prevents interruption of therapy by patients who were not warned for neuropsychiatric side effects. Furthermore, patients should report in case of rapidly arising mood disorders. Interferon-alfa induced mood disorder is reported to be treatable. Three case descriptions illustrate this, but also illustrate some limits to successful treatment. Copyright © Cambridge University Press 1999 interferon nationallicence psychiatric nationallicence side effects nationallicence Van Gool A.R. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Psychosocial Oncology Kruit W.H.J. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Internal Oncology Cornelissen J.J. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Hematology Berk L. Albert Schweitzer Hospital, Department of Internal Medicine, Zwijndrecht Eggermont A.M.M. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Surgical Oncology Bannink M. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Psychosocial Oncology Acta Neuropsychiatrica Cambridge University Press 11/4(1999-12), 120-124 0924-2708 11:4<120 1999 11 NEU https://doi.org/10.1017/S0924270800035857 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S0924270800035857 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Van Gool A.R. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Psychosocial Oncology NATIONALLICENCE 700 1- Kruit W.H.J. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Internal Oncology NATIONALLICENCE 700 1- Cornelissen J.J. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Hematology NATIONALLICENCE 700 1- Berk L. Albert Schweitzer Hospital, Department of Internal Medicine, Zwijndrecht NATIONALLICENCE 700 1- Eggermont A.M.M. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Surgical Oncology NATIONALLICENCE 700 1- Bannink M. University Hospital Rotterdam - Daniel Oncology Clinic, Department of Psychosocial Oncology NATIONALLICENCE 773 0- Acta Neuropsychiatrica Cambridge University Press 11/4(1999-12), 120-124 0924-2708 11:4<120 1999 11 NEU CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge